Danaher's Preliminary 4Q Seen as Promising -- Market Talk
Dow Jones01-15
1530 ET - Danaher's preliminary 4Q results show a good close to 2025, Morgan Stanley analysts say. The analysts say they are encouraged by stated outperformance in both life sciences and diagnostics during the quarter, which are two areas where the analysts see upside risk in 2026 and 2027. Top line results were driven by continued strength in bioprocessing, as well. The analysts expect management to continue highlighting uptake of innovative instruments and assays in areas like pathology and immunoassay through the year. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
January 14, 2026 15:30 ET (20:30 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments